| 1 - Background of the Course.mp4 | 95.8 MB | ||
| 1 - Multiple Choice.html | 0 B | ||
| 10 - Course Questions.html | 3.9 KB | ||
| 10 - Course-Questions-Coronavirus-Story.pdf | 128.2 KB | ||
| 10 - Multiple Choice.html | 0 B | ||
| 100 - 5 Anticoagulants and COVID19 Biomarkers – Part Two.html | 3.2 KB | ||
| 100 - Anticoagulants-and-COVID-19-Biomarkers-2.pdf | 138.9 KB | ||
| 101 - 6 NSAIDs Usage in Covid19 Patients.mp4 | 22.4 MB | ||
| 102 - 6 NSAIDs Usage in Covid19 Patients.html | 1.6 KB | ||
| 102 - NSAIDs-Usage-in-Covid-19-Patients-Coronavirus-story.pdf | 125.3 KB | ||
| 103 - 7 Bronchodilators Usage in Covid19 Patients.mp4 | 4 MB | ||
| 104 - 7 Bronchodilators Usage in Covid19 Patients.html | 1.1 KB | ||
| 104 - Bronchodilators-Usage-in-Covid-19-Patients-Coronavirus-story.pdf | 82.9 KB | ||
| 105 - 8 Gastrointestinal Agents Usage in COVID19 Patients.mp4 | 6.4 MB | ||
| 106 - 8 Gastrointestinal Agents Usage in COVID19 Patients.html | 1.6 KB | ||
| 106 - Gastrointestinal-Agents-Usage-in-COVID-19-Patients-Coronavirus-Story.pdf | 125.3 KB | ||
| 107 - 9 Antihypertensive Drugs Usage in COVID19 Patients.mp4 | 5.3 MB | ||
| 108 - 9 Antihypertensive Drugs Usage in COVID19 Patients.html | 2.2 KB | ||
| 108 - Antihypertensive-Drugs-Usage-in-COVID-19-Patients-Coronavirus-Story.pdf | 127.4 KB | ||
| 109 - ECMO Machine HighFlow Oxygen Fluid management and Spirometer Use.mp4 | 78.9 MB | ||
| 11 - Multiple Choice.html | 0 B | ||
| 11 - Significance of the Course.mp4 | 24.8 MB | ||
| 110 - ECMO Machine HighFlow Oxygen Fluid management and Spirometer Use.html | 4.6 KB | ||
| 110 - ECMO-Machine-High-Flow-Oxygen-Fluid-management-and-Spirometer-Use-Coronavirus-Story.pdf | 132.7 KB | ||
| 111 - Drug Repurposing A Prosperous Tactic.mp4 | 20.1 MB | ||
| 112 - Drug Repurposing A Prosperous Tactic.html | 4.6 KB | ||
| 112 - Drug-Repurposing-Coronavirus-Story.pdf | 145.7 KB | ||
| 113 - The COVID19 Vaccine Scheme.mp4 | 54.7 MB | ||
| 114 - The COVID19 Vaccine Scheme.html | 2.8 KB | ||
| 114 - The-COVID-19-Vaccine-Scheme-Coronavirus-Story.pdf | 127.8 KB | ||
| 115 - The Improvement of SARSCoV2 Vaccines.mp4 | 19 MB | ||
| 116 - The Improvement of SARSCoV2 Vaccines.html | 3.9 KB | ||
| 116 - The-Improvement-of-SARS-CoV-2-Vaccines-Coronavirus-Story.pdf | 134.4 KB | ||
| 117 - Vaccine Platforms.mp4 | 13.5 MB | ||
| 118 - Vaccine Platforms.html | 4.3 KB | ||
| 118 - Vaccine-Platforms-Coronavirus-Story.pdf | 140.1 KB | ||
| 119 - Summary.mp4 | 106.8 MB | ||
| 12 - Multiple Choice.html | 0 B | ||
| 12 - Significance of the Course.html | 5.1 KB | ||
| 12 - Significance-of-the-Course-Coronavirus-Story.pdf | 130.1 KB | ||
| 120 - Summary-Coronavirus-Story.pdf | 138.9 KB | ||
| 120 - Summary.html | 4.4 KB | ||
| 121 - Future Work and Recommendations.mp4 | 24.6 MB | ||
| 122 - Future Work and Recommendations.html | 4.8 KB | ||
| 122 - Future-Work-and-Recommendations-Coronavirus-Story.pdf | 88.3 KB | ||
| 123 - Limitations.mp4 | 28.2 MB | ||
| 124 - Limitations-Coronavirus-Story.pdf | 138.8 KB | ||
| 124 - Limitations.html | 5.7 KB | ||
| 125 - Abbreviations.mp4 | 7.5 MB | ||
| 126 - Abbreviations-Coronavirus.pdf | 85 KB | ||
| 126 - Abbreviations.html | 1.7 KB | ||
| 127 - The Course Articles Part One.mp4 | 55.9 MB | ||
| 128 - The Course Articles Part Two.mp4 | 49 MB | ||
| 129 - The Course Articles Part Three.mp4 | 48.8 MB | ||
| 13 - Maram Shtaya Approach.mp4 | 77.9 MB | ||
| 13 - Multiple Choice.html | 0 B | ||
| 130 - Curriculum of the Course.mp4 | 12.2 MB | ||
| 131 - Resources of Course Material.mp4 | 56 MB | ||
| 131 - Resources-Coronavirus-Story-Perception.pdf | 350.1 KB | ||
| 132 - Bonus Lecture with Updated Discount Coupons.html | 13.8 KB | ||
| 14 - Maram Shtaya Approach.html | 3.3 KB | ||
| 14 - Maram-Shtaya-Approach-Coronavirus-Story.pdf | 137.7 KB | ||
| 14 - Multiple Choice.html | 0 B | ||
| 15 - Multiple Choice.html | 0 B | ||
| 15 - Significance of Maram Shtaya Approach.mp4 | 16.3 MB | ||
| 16 - Multiple Choice.html | 0 B | ||
| 16 - Significance of Maram Shtaya Approach.html | 3.4 KB | ||
| 16 - Significance-of-Maram-Shtaya-Approach-Coronavirus-Sory.pdf | 128.7 KB | ||
| 17 - 1 Transtheoretical Model TTM.mp4 | 48.6 MB | ||
| 17 - Multiple Choice.html | 0 B | ||
| 18 - 1 Transtheoretical Model TTM.html | 3.2 KB | ||
| 18 - Multiple Choice.html | 0 B | ||
| 18 - Transtheoretical-Model-Coronavirus-Story.pdf | 137.7 KB | ||
| 19 - The Four Structures of the TTM.mp4 | 16.3 MB | ||
| 2 - Background of the Course.html | 6.2 KB | ||
| 2 - Background-of-the-Course-Coronavirus-Story.pdf | 142.5 KB | ||
| 2 - Multiple Choice.html | 0 B | ||
| 20 - The Four Structures of the TTM.html | 3.4 KB | ||
| 20 - The-Four-Structures-of-the-TTM-Coronavirus-Story.pdf | 128.4 KB | ||
| 21 - 2 Protection Motivation Theory PMT.mp4 | 6.1 MB | ||
| 22 - 2 Protection Motivation Theory PMT.html | 1.9 KB | ||
| 22 - Protection-Motivation-Theory-Coronavirus-Story.pdf | 125.4 KB | ||
| 23 - The Structure of Protection Motivation Theory PMT.mp4 | 9.3 MB | ||
| 24 - The Structure of Protection Motivation Theory PMT.html | 2.2 KB | ||
| 24 - The-Structure-of-Protection-Motivation-Theory-Coronavirus-Story.pdf | 167.9 KB | ||
| 25 - 3 KAP Survey Model.mp4 | 24.1 MB | ||
| 26 - 3 KAP Survey Model.html | 1.3 KB | ||
| 26 - KAP-Survey-Model-Coronavirus-Story.pdf | 134.2 KB | ||
| 27 - 4 Communication Theory.mp4 | 7.6 MB | ||
| 28 - 4 Communication Theory.html | 2.8 KB | ||
| 28 - Communication-Theory-Coronavirus-Story.pdf | 134.9 KB | ||
| 29 - 5 Normalisation Process Theory NPT.mp4 | 9.1 MB | ||
| 3 - Literature Review.mp4 | 19.6 MB | ||
| 3 - Multiple Choice.html | 0 B | ||
| 30 - 5 Normalisation Process Theory NPT.html | 2.3 KB | ||
| 30 - Normalisation-Process-Theory-Coronavirus-Story.pdf | 127.2 KB | ||
| 31 - The Normalisation Process Theory NPT Prime Elements.mp4 | 7.6 MB | ||
| 32 - The Normalisation Process Theory NPT Prime Elements.html | 1.9 KB | ||
| 32 - The-Normalisation-Process-Theory-Coronavirus-Story.pdf | 83.7 KB | ||
| 33 - 6 Holism Theory.mp4 | 9.1 MB | ||
| 34 - 6 Holism Theory.html | 1.8 KB | ||
| 34 - Holism-Theory-Coronavirus-Story.pdf | 125.5 KB | ||
| 35 - 7 Complexity Theory.mp4 | 4.8 MB | ||
| 36 - 7 Complexity Theory.html | 1.7 KB | ||
| 36 - Complexity-Theory-Coronavirus-Story.pdf | 125 KB | ||
| 37 - Coronavirus Expression.mp4 | 64.4 MB | ||
| 38 - Coronavirus Expression.html | 3.6 KB | ||
| 38 - Coronavirus-Expression-Coronavirus-Story.pdf | 143 KB | ||
| 39 - The Four Coronavirus Genera.mp4 | 10.6 MB | ||
| 4 - Literature Review.html | 6.9 KB | ||
| 4 - Literature-Review-Coronavirus-Story.pdf | 152.5 KB | ||
| 4 - Multiple Choice.html | 0 B | ||
| 40 - The Four Coronavirus Genera.html | 2.7 KB | ||
| 40 - The-Four-Coronavirus-Genera-Coonavirus-Story.pdf | 136.6 KB | ||
| 41 - Severe Acute Respiratory Syndrome Coronavirus SARSCoV.mp4 | 25.7 MB | ||
| 42 - Severe Acute Respiratory Syndrome Coronavirus SARSCoV.html | 1.9 KB | ||
| 42 - Severe-Acute-Respiratory-Syndrome-Coronavirus-Coronavirus-Story.pdf | 83.8 KB | ||
| 43 - Middle East Respiratory Syndrome Coronavirus MERSCoV.mp4 | 6.2 MB | ||
| 44 - Middle East Respiratory Syndrome Coronavirus MERSCoV.html | 2.1 KB | ||
| 44 - Middle-East-Respiratory-Syndrome-Coronavirus-Coronavirus-Story.pdf | 127.2 KB | ||
| 45 - The Coronavirus Genome and Structure.mp4 | 7.2 MB | ||
| 46 - The Coronavirus Genome and Structure.html | 1.9 KB | ||
| 46 - The-Coronavirus-Genome-and-Structure-Coronavirus-Story.pdf | 125.4 KB | ||
| 47 - The Epidemiologic Coronavirus Realization.mp4 | 40.7 MB | ||
| 48 - The Epidemiologic Coronavirus Realization.html | 2.4 KB | ||
| 48 - The-Epidemiologic-Coronavirus-Realization-Coronavirus-Story.pdf | 127.5 KB | ||
| 49 - Coronavirus Expansion A Central Worry.mp4 | 13.2 MB | ||
| 5 - Multiple Choice.html | 0 B | ||
| 5 - Statement of the Problem and Rational of the Course.mp4 | 20.3 MB | ||
| 50 - Coronavirus Expansion A Central Worry.html | 3.5 KB | ||
| 50 - Coronavirus-Expansion-Coronavirus-Story.pdf | 141.3 KB | ||
| 51 - Coronavirus Phylogenetics and Taxonomy Alphacoronavirus.mp4 | 9.9 MB | ||
| 52 - Coronavirus Phylogenetics and Taxonomy Alphacoronavirus.html | 2.6 KB | ||
| 52 - Coronavirus-Phylogenetics-and-Taxonomy-Alphacoronavirus-Coronavirus-Story.pdf | 127.6 KB | ||
| 53 - Coronavirus Phylogenetics and Taxonomy – Betacoronavirus Part One.mp4 | 9.2 MB | ||
| 54 - Coronavirus Phylogenetics and Taxonomy – Betacoronavirus Part One.html | 2.7 KB | ||
| 54 - Coronavirus-Phylogenetics-and-Taxonomy-Betacoronavirus-1-Coronavirus-Story.pdf | 128.4 KB | ||
| 55 - Coronavirus Phylogenetics and Taxonomy – Betacoronavirus Part Two.mp4 | 13 MB | ||
| 56 - Coronavirus Phylogenetics and Taxonomy – Betacoronavirus Part Two.html | 2.9 KB | ||
| 56 - Coronavirus-Phylogenetics-and-Taxonomy-Betacoronavirus-2-Coronavirus-Story.pdf | 170.8 KB | ||
| 57 - Coronavirus Pathogenesis.mp4 | 56.7 MB | ||
| 58 - Coronavirus Pathogenesis.html | 3.4 KB | ||
| 58 - Coronavirus-Pathogenesis-Coronavirus-Story.pdf | 142 KB | ||
| 59 - Coronavirus Proteins Receptor Interaction Incorporation and Entrance.mp4 | 10.4 MB | ||
| 6 - Multiple Choice.html | 0 B | ||
| 6 - Statement of the Problem and Rational of the Course.html | 3.2 KB | ||
| 6 - Statement-of-the-Problem-and-Rational-of-the-Course-Coronavirus-Story.pdf | 85.4 KB | ||
| 60 - Coronavirus Proteins Receptor Interaction Incorporation and Entrance.html | 3.3 KB | ||
| 60 - Coronavirus-Proteins-Coronavirus-Story.pdf | 128.5 KB | ||
| 61 - Acute Respiratory Tract Contagions.mp4 | 63.8 MB | ||
| 62 - Acute Respiratory Tract Contagions.html | 4.2 KB | ||
| 62 - Acute-Respiratory-Tract-Contagions-Coronavirus-Story.pdf | 246.2 KB | ||
| 63 - An Essential Reason of Pneumonia.mp4 | 10.5 MB | ||
| 64 - An Essential Reason of Pneumonia.html | 2.7 KB | ||
| 64 - An-Essential-Reason-of-Pneumonia-Coronavirus-Story.pdf | 137.6 KB | ||
| 65 - Hypoxaemia and Acute Respiratory Distress Syndrome ARDS.mp4 | 6.4 MB | ||
| 66 - Hypoxaemia and Acute Respiratory Distress Syndrome ARDS.html | 2.3 KB | ||
| 66 - Hypoxaemia-and-Acute-Respiratory-Distress-Syndrome-Coronavirus-Story.pdf | 127.5 KB | ||
| 67 - Coronaviruses CoVs Effects on Humans and Animals.mp4 | 65.9 MB | ||
| 68 - Coronaviruses CoVs Effects on Humans and Animals.html | 4.2 KB | ||
| 68 - Coronaviruses-Effects-on-Humans-and-Animals-Coronavirus-Story.pdf | 131.1 KB | ||
| 69 - Urbanization Consequences.mp4 | 12.5 MB | ||
| 7 - Multiple Choice.html | 0 B | ||
| 7 - Objectives of the Course.mp4 | 120.5 MB | ||
| 70 - Urbanization Consequences.html | 3.8 KB | ||
| 70 - Urbanization-Consequences-Coronavirus-Story.pdf | 137.8 KB | ||
| 71 - Coronavirus Control Procedures.mp4 | 45.4 MB | ||
| 72 - Coronavirus Control Procedures.html | 2.7 KB | ||
| 72 - Coronavirus-Control-Procedures-Coronavirus-Story.pdf | 136 KB | ||
| 73 - After Exposure to Somebody Who has COVID19.mp4 | 13.7 MB | ||
| 74 - After Exposure to Somebody Who has COVID19.html | 3.2 KB | ||
| 74 - After-Exposure-to-Somebody-Who-has-COVID-19-Coronavirus-Story.pdf | 142.5 KB | ||
| 75 - SARS‑CoV‑2 Virus and COVID19 Disease.mp4 | 39.8 MB | ||
| 76 - SARS-CoV-2-Virus-and-COVID-19-Disease-Coronavirus-Story.pdf | 152 KB | ||
| 76 - SARS‑CoV‑2 Virus and COVID19 Disease.html | 3 KB | ||
| 77 - COVID19 Symptoms.mp4 | 15.1 MB | ||
| 78 - COVID-19-Symptoms-Coronavirus-Story.pdf | 244.8 KB | ||
| 78 - COVID19 Symptoms.html | 3.6 KB | ||
| 79 - Procalcitonin A BacteriaParticular Biomarker.mp4 | 23.8 MB | ||
| 8 - Multiple Choice.html | 0 B | ||
| 8 - Objectives of the Course.html | 4.5 KB | ||
| 8 - Objectives-of-the-Course-Coronavirus-Story.pdf | 136.2 KB | ||
| 80 - Procalcitonin A BacteriaParticular Biomarker.html | 1.7 KB | ||
| 80 - Procalcitonin-Coronavirus-Story.pdf | 125.2 KB | ||
| 81 - Antibody Responses to SARSCoV2 A Pivotal Concern.mp4 | 12.1 MB | ||
| 82 - Antibody Responses to SARSCoV2 A Pivotal Concern.html | 3.7 KB | ||
| 82 - Antibody-Responses-to-SARS-CoV-2-Coronavirus-Story.pdf | 129.5 KB | ||
| 83 - Suggestions Concerning Health Communication.mp4 | 12.3 MB | ||
| 84 - Suggestions Concerning Health Communication.html | 2.6 KB | ||
| 84 - Suggestions-Concerning-Health-Communication-Coronavirus-story.pdf | 143.4 KB | ||
| 85 - Nutrition A Determinant Agent for Homeostasis.mp4 | 65.1 MB | ||
| 86 - Nutrition A Determinant Agent for Homeostasis.html | 3.8 KB | ||
| 86 - Nutrition-Coronavirus-Stroy.pdf | 136.4 KB | ||
| 87 - Some of Probable Therapeutics for Patients with Coronavirus.mp4 | 10.3 MB | ||
| 88 - Some of Probable Therapeutics for Patients with Coronavirus.html | 3.9 KB | ||
| 88 - Some-of-Probable-Therapeutics-for-Patients-with-Coronavirus-Coronavirus-Story.pdf | 139.3 KB | ||
| 89 - Pharmacological Treatment 1 Antimicrobials Usage in Covid19 Patients.mp4 | 13.4 MB | ||
| 9 - Course Questions.mp4 | 22.6 MB | ||
| 9 - Multiple Choice.html | 0 B | ||
| 90 - Antimicrobials-Usage-in-Covid-19-Coronavirus-Story.pdf | 140.4 KB | ||
| 90 - Pharmacological Treatment 1 Antimicrobials Usage in Covid19 Patients.html | 4.5 KB | ||
| 91 - 2 Corticosteroid Usage in Patients with Coronavirus.mp4 | 15.8 MB | ||
| 92 - 2 Corticosteroid Usage in Patients with Coronavirus.html | 4.8 KB | ||
| 92 - Corticosteroid-Usage-in-Patients-with-Coronavirus-Coronavirus-Story.pdf | 140.8 KB | ||
| 93 - 3 Antimalarial and Antiviral Agents Use in Covid19 Patients.mp4 | 9.2 MB | ||
| 94 - 3 Antimalarial and Antiviral Agents Use in Covid19 Patients.html | 2.5 KB | ||
| 94 - Antimalarial-and-Antiviral-Agents-Use-in-Covid-19-Coronavirus-Story.pdf | 127.8 KB | ||
| 95 - 4 Nacetylcysteine Usage in Covid19 Patients.mp4 | 37 MB | ||
| 96 - 4 Nacetylcysteine Usage in Covid19 Patients.html | 1.9 KB | ||
| 96 - N-acetylcysteine-Usage-in-Covid-19-Patients-Coronavirus-Story.pdf | 126 KB | ||
| 97 - 5 Anticoagulants and COVID19 Biomarkers – Part One.mp4 | 13.1 MB | ||
| 98 - 5 Anticoagulants and COVID19 Biomarkers – Part One.html | 3.5 KB | ||
| 98 - Anticoagulants-and-COVID-19-Biomarkers.pdf | 129.2 KB | ||
| 99 - 5 Anticoagulants and COVID19 Biomarkers – Part Two.mp4 | 11 MB | ||
| Bonus Resources.txt | 409.6 B | ||
| Get Bonus Downloads Here.url | 204.8 B | ||
| ▲ 216 total files | |||
Coronavirus Story Perception By Using Maram Shtaya Approach
https://CourseWikia.com
Last updated 4/2024
MP4 | Video: h264, 1280x720 | Audio: AAC, 44.1 KHz
Language: English (US) | Size: 1.88 GB | Duration: 5h 21m
Maram Shtaya Approach, Coronavirus Genome, Structure, Pathogenesis, and Treatment, COVID-19 Disease and Symptoms
What you'll learn
Maram Shtaya Approach
Significance of Maram Shtaya Approach
Transtheoretical Model (TTM)
The Four Structures of the TTM
Protection Motivation Theory (PMT)
The Structure of Protection Motivation Theory (PMT)
KAP Survey Model
Communication Theory
Normalisation Process Theory (NPT)
The Normalisation Process Theory (NPT) Prime Elements
Holism Theory
Complexity Theory
Coronavirus Expression
The Four Coronavirus Genera
Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
The Coronavirus Genome and Structure
The Epidemiologic Coronavirus Realization
Coronavirus Expansion: A Central Worry
Coronavirus Phylogenetics and Taxonomy
Coronavirus Pathogenesis
Coronavirus Proteins, Receptor Interaction, Incorporation, and Entrance
Acute Respiratory Tract Contagions
An Essential Reason of Pneumonia
Hypoxaemia and Acute Respiratory Distress Syndrome (ARDS)
Coronaviruses (CoVs) Effects on Humans and Animals
Urbanization Consequences
Coronavirus Control Procedures
After Exposure to Somebody Who has COVID-19
SARS‑CoV‑2 Virus and COVID-19 Disease
COVID-19 Symptoms
Procalcitonin: A Bacteria-Particular Biomarker
Antibody Responses to SARS-CoV-2: A Pivotal Concern
Suggestions Concerning Health Communication
Nutrition: A Determinant Agent for Homeostasis
Some of Probable Therapeutics for Patients with Coronavirus
Antimicrobials Usage in Covid-19 Patients
Corticosteroid Usage in Patients with Coronavirus
Antimalarial and Antiviral Agents Use in Covid-19 Patients
N-acetylcysteine Usage in Covid-19 Patients
Anticoagulants and COVID-19 Biomarkers
NSAIDs Usage in Covid-19 Patients
Bronchodilators Usage in Covid-19 Patients
Gastrointestinal Agents Usage in COVID-19 Patients
Antihypertensive Drugs Usage in COVID-19 Patients
ECMO Machine, High-Flow Oxygen, Fluid management, and Spirometer Use
Drug Repurposing: A Prosperous Tactic
The COVID-19 Vaccine Scheme
The Improvement of SARS-CoV-2 Vaccines
Vaccine Platforms
Requirements
There are no prerequisites for this course; but a passion to read, understand and/or realize Coronavirus Story.
| torrent name | size | uploader | age | seed | leech |
|---|---|---|---|---|---|
|
[ FreeCourseWeb ] Udemy - Flutter REST API Crash Course - Build a Coronavirus App Posted by
freecoursewb in Other
|
1.3 GB | freecoursewb | 6 years | 1 | 0 |
|
[ FreeCourseWeb ] Udemy - Personal Emergency Planning (Coronavirus - COVID-19 Edition) Posted by
freecoursewb in Other
|
680.3 MB | freecoursewb | 6 years | 0 | 0 |
All Comments